Amgen Inc (HKSE:04332)
HK$ 1761 0 (0%) Market Cap: 1.18 Til Enterprise Value: 1.58 Til PE Ratio: 36.22 PB Ratio: 20.20 GF Score: 92/100

Amgen Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2022 / 04:15PM GMT
Release Date Price: HK$1850
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

Great. Good morning, everyone, from the 40th Annual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the senior large-cap biotech analyst, and it's my pleasure to introduce Amgen, and Chairman and CEO, Bob Bradway.

Please note that following the presentation, we will move right into a Q&A session where you can send in questions via the conference portal, and I'll do my best to work them into the conversation.

So with that, Bob, thanks, as always, for joining us today, and let me turn things over to you for an update.

Robert A. Bradway
Amgen Inc. - Chairman, CEO & President

Okay. Cory, thanks very much. Happy New Year to you and thanks for having us again this year. We're excited to be here. As we look at 2022 and beyond, we think things are setting up pretty well for us to be able to deliver attractive long-term growth for our shareholders. And so I'd like to talk a little bit about that in our time together this morning.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot